A New Era for Childhood Deafness: Gene Therapy Restores Hearing in Both Ears

Redacción HC
06/06/2024

In a groundbreaking clinical advance, a team of researchers from Fudan University in Shanghai and Mass Eye and Ear in Boston has reported the first successful use of bilateral gene therapy to restore hearing in children with a rare inherited form of deafness. The study, published in Nature Medicine, presents the outcomes of a phase I/II clinical trial treating five children with autosomal recessive deafness 9 (DFNB9), a genetic condition caused by mutations in the OTOF gene.

For families facing the reality of congenital deafness, these findings offer more than just hope—they signal a paradigm shift in auditory medicine, where a single gene therapy injection may enable natural, binaural hearing in young children.

Addressing a Silent Start: The Clinical Challenge

DFNB9 leads to profound prelingual hearing loss, depriving children of auditory perception from birth. Traditional treatments, such as cochlear implants, offer partial restoration but often fall short in noisy environments and fail to replicate the natural directionality of sound—two critical components for language development and safe navigation.

The key research question posed by the study was clear:

Can a single, bilateral injection of the gene therapy AAV1-hOTOF safely and effectively restore functional hearing in both ears of children with DFNB9?

Inside the Trial: From Design to Delivery

This single-arm, open-label trial enrolled five pediatric patients with confirmed OTOF mutations and hearing thresholds above 95 dB—indicative of profound deafness. Each child received a one-time injection of AAV1-hOTOF (1.5 × 10¹² vg) into both cochleae via the round window during a single surgical session.

Safety Monitoring and Outcome Measures

• Primary objective: Assess short-term safety and detect any dose-limiting toxicities over six weeks.
• Secondary objectives: Measure auditory thresholds via ABR and ASSR, evaluate speech perception, sound localization, and clinical auditory behavior through tools like MAIS, IT-MAIS, CAP, MUSS, and SSQ-P.
• Immune response: Analyzed using neutralizing antibody titers and IFN-γ ELISpot assays to track potential immune reactions.

Results That Speak Volumes: What the Children Gained

1. Safety Confirmed

• No serious adverse events were recorded.
• Minor side effects (e.g., elevated white cells or lipid levels) occurred in 36 instances (grades 1–2).
• Imaging confirmed that cochlear structures remained intact post-surgery.
• While anti-AAV1 antibodies increased significantly, no acute T-cell responses were detected.

2. Remarkable Hearing Recovery

All five children exhibited bilateral restoration of hearing:

• Patient 1: ABR thresholds improved to 58 dB in both ears at 26 weeks.
• Patients 4 and 5: Showed binaural improvements to 75/78 dB and 63/63 dB, respectively, by week 13.
• ASSR data revealed that bilateral therapy was more effective than previous unilateral approaches (average 60 dB vs. 67 dB in one ear).

3. Speech Perception and Sound Localization

Children gained functional speech perception and were able to localize sound sources—a critical skill for everyday communication and safety.

"Two of the children even responded to music, showing behaviors like dancing or rhythmic movement," the researchers reported.

Beyond the Cochlea: Broader Clinical and Social Impacts

Redefining Treatment for Genetic Deafness

This is the first clinical study to demonstrate that gene therapy can be safely delivered to both ears in human patients, with clear binaural functional gains. The trial builds upon prior research that tested unilateral injections, which restored partial hearing in 5 of 6 participants but lacked directional perception.

The bilateral approach revealed enhanced outcomes in spatial hearing and environmental awareness, which are especially important in childhood development.

Implications for Healthcare Systems

• A new therapeutic alternative to cochlear implants with potential for permanent correction of genetic deafness.
• May reduce long-term dependency on auditory devices, therapy, and special education.
• Offers insights for future precision medicine trials targeting other genetic variants of deafness.

Enhancing Quality of Life

The study underscores how hearing is more than a medical condition—it's a gateway to connection, learning, and emotional well-being. Children who regained sound perception can now participate in school, socialize more naturally, and experience the world in stereo.

Future Horizons and Recommendations

The researchers call for:

1. Larger clinical trials with more diverse populations.
2. Long-term follow-up to monitor sustained efficacy and immune responses.
3. Development of therapies for additional genetic hearing loss subtypes.
4. Integration of psychosocial and developmental metrics in future trials.

A Global Relevance: What It Means for Latin America

DFNB9 is not geographically limited. Studies have documented OTOF mutations in regions including Mexico, Brazil, Chile, and Peru. This opens the door for regional trials and treatment programs across Latin America—especially in countries with expanding pediatric genetic screening.

By investing in gene therapy infrastructure, local healthcare systems can move toward personalized auditory care, potentially reducing disability burdens and improving inclusion.

Conclusion: Two Ears, One Leap Toward the Future

This study is more than a medical success—it represents a new frontier in auditory medicine, combining molecular biology, surgical precision, and compassionate care.

As one parent reportedly said, "It's like watching our child meet the world for the first time—through sound."

With safe and effective bilateral gene therapy, the silence of congenital deafness may one day be a thing of the past.

Topics of interest

Health